

Committee membership list – Chronic heart failure guideline Committee

Membership of Chronic heart failure guideline Committee

The Committee will operate as an advisory Committee to NICE's Board, developing a guideline on Chronic heart failure

The terms of reference and standing orders for the Committee can be found in [appendix D of Developing NICE guidelines: the manual](#).

The Committee has 11 members.

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

Membership list

Role	Name	Job Title, Organisation
Chair		
Chair	Anthony Wierzbicki	Consultant in Metabolic Medicine and Chemical Pathology, Guys & St. Thomas' NHS Trust
Core members		
Cardiologist (Early GC Member)	Abdallah Al-Mohammad	Consultant Cardiologist, Northern General Hospital
Cardiologist	Martin Cowie (<i>resigned December 2016</i>)	Honorary Consultant Cardiologist, Royal Brompton & Harefield NHS Trust
Cardiologist (Community)	Suzanna Hardman	Consultant Cardiologist with an Interest in Community Cardiology, Whittington Health
GP with specialist interest	Clare Taylor	General Practitioner, University of Birmingham
GP with specialist interest	Jim Moore	General Practitioner, Cheltenham
Specialist Nurse (HF nurse)	Sue Simpson	Head of Cardiac Care, Oxleas NHS Trust
Physician in elderly care/Geriatrician	Rebecca Schiff	Consultant Geriatrician and General Physician, Guy's and St Thomas' NHS Trust
Pharmacist	Rani Khatib	Consultant Pharmacist Cardiology & Cardiovascular Clinical Research, Leeds Teaching Hospitals NHS Trust
Lay member	Richard Mindham	-
Lay member	Nick Hartshorne-Evans	-
Topic expert members		
Nephrologist	Vacant – readvertised	-
Rehabilitation professional	Vacant – readvertised	-

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

Date last reviewed: 30/03/2016

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

Declaration of Interests

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Anthony Wierzbicki	Consultant Chemical Pathologist, Guys & St. Thomas' NHS Trust and Honorary Reader (Assistant Professor) in Lipids and Cardiometabolic Disease, King's College London	Clinical Investigator for Trust hospital on studies of lipid-lowering compounds for Merck; Pfizer and Amgen.	Non-personal, financial, non-specific	Declare and participate
Anthony Wierzbicki	Consultant Chemical Pathologist, Guys & St. Thomas' NHS Trust and Honorary Reader (Assistant Professor) in Lipids and Cardiometabolic Disease, King's College London	Commercially funded registry (GENIALL) for lipoprotein lipase deficiency (Chiesi)	Non-personal, financial, non-specific	Declare and participate
Abdallah Al-Mohammad	Consultant Cardiologist & Honorary Senior Clinical Lecturer, Northern General Hospital, Sheffield	Accepted hospitality (air travel and hotel) to attend the ESC-Heart Failure Meeting in Athens 2014 and in Seville 2015 from Servier.	Personal, financial, non-specific	Declare and participate

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

	Teaching Hospitals NHS Trust			
Abdallah Al-Mohamm ad	Consultant Cardiologist & Honorary Senior Clinical Lecturer, Northern General Hospital, Sheffield Teaching Hospitals NHS Trust	Holder of a grant for Sheffield Teaching Hospitals Charitable Trust for partial funding of the Sheffield Contribution to the International Study of Sildenafil in the treatment of patients with heart failure due to left ventricular systolic dysfunction and raised pulmonary artery hypertension (SILHF trial).	Non-personal, financial, non-specific	Declare and participate
Abdallah Al-Mohamm ad	Consultant Cardiologist & Honorary Senior Clinical Lecturer, Northern General Hospital, Sheffield Teaching Hospitals NHS Trust	<p>Currently the principal investigator in Sheffield for SILHF, PARAGON, LIVE:LIFE trials. I am co-principal investigator in Sheffield for REVIVED trial.</p> <p>PARAGON: a trial sponsored by Novartis of LCZ696 in patients with heart failure with preserved left ventricular ejection fraction.</p> <p>LIVE:LIFE: a trial sponsored by Servier of the quality of life of patients with heart failure with impaired left ventricular systolic function who are in sinus rhythm, over 70 years of age. We have completed the recruitment into this study. (Involvement with this stopped over a year ago)</p> <p>REVIVED: is a trial of percutaneous coronary intervention or medical therapy in patients with severe left ventricular systolic impairment and</p>	Non-personal, financial, non-specific	Declare and participate

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

		coronary artery disease with evidence on cardiac MRI of sufficient hibernating myocardium. The funding is from NIHR.		
Clare Taylor	General Practitioner, University of Birmingham	<p>Is an academic GP, funded by the NIHR to undertake research and teaching in the area of heart failure</p> <p>Starts an NIHR-funded Academic Clinical Lecturer post at the University of Oxford on 31st March 2016</p> <p>Has been involved in a diagnostic accuracy study (the 'REFER' study) examining the effectiveness of a clinical decision rule in identifying patients with heart failure and a heart failure screening study (ECHOES-X) which followed up patients screened for heart failure in the late 1990s to see who had developed the disease over time.</p>	Personal, financial, non-specific	Declare and participate
Martin Cowie	Honorary Consultant Cardiologist, Royal Brompton & Harefield NHS Trust	Research grants to Imperial College from: ResMed (Sleep apnoea in heart failure – not relevant to the scope of this guidelines), Boston Scientific (sleep apnoea algorithm in pacemakers – not relevant to scope of this guideline), Bayer (prevalence of atrial fibrillation in people with a defibrillator/pacemaker – epidemiological study not relevant to any product discussed in the scope of the guideline)	Non-personal, financial, non-specific and specific	<p>Declare and participate</p> <p>May be required to declare and withdraw if telemonitoring when is considered.</p>
Martin Cowie	Honorary Consultant Cardiologist,	Consultancy agreements/speaker fees for specific input from:	Personal, financial,	Declare and participate

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

	Royal Brompton & Harefield NHS Trust	ResMed (sleep apnoea in heart failure – not in scope of guidelines), Boston Scientific, Medtronic, St Jude Medical, (all three relate to funding of a randomised trial of remote monitoring of implanted devices (Rem-HF) that is due to complete in next month and thereafter support stops - not relevant to this guideline) Servier (manufactures ivabradine), Bayer (manufactures rivaroxaban, which is not a specific drug for heart failure and is not in scope of this guideline), Novartis (lecture on use of this drug in clinical practice and worked with their cost-effectiveness team on preparing the dossier for NICE).	non-specific Servier and Novartis personal, financial specific	May be required to declare and withdraw if Ivabradine (Servier) and sacubitril/valsartan (Novartis) considered
Rani Khatib	Consultant Pharmacist Cardiology & Cardiovascular Clinical Research, Leeds Teaching Hospitals NHS Trust	Novartis: Educational Grant covering travel, accommodation and conference fees to attend the HF SUMMIT 2015 – PACE. Consultancy fee for attending “Implementation of a new HF treatment” advisory meeting in November 2015. Servier: Educational Grant covering travel, accommodation and conference fees to attend the ESC Congress 2015. AstraZeneca: Service Development / Research grant as part of a joint working partnership with Leeds Teaching Hospitals on Post MI Medicines Optimisation Clinic (January – Dec 2016).	Personal, financial, non-specific and specific (Servier, Novartis)	Declare and participate May be required to declare and withdraw if Ivabradine (Servier) and sacubitril/valsartan (Novartis) considered

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

		<p>Sponsorship of the Yorkshire and North-east Cardiovascular Pharmacy Network (YNCPN) educational meeting in February 2016 titled “ACS management update” – sponsorship included venue, equipment, food and speakers’ fees.</p> <p>Daiichi Sankyo: Sponsorship of Yorkshire and North-east Cardiovascular Pharmacy Network (YNCPN) Sept 2015 educational meeting “antiplatelets update”. Sponsorship included venue, equipment, food and speakers’ fees.</p>		
Jim Moore	General Practitioner, Cheltenham	<p>Received honoraria, travel and accommodation from Novartis for Advance Heart Failure steering committee and Heart Failure Speaker Faculty meetings.</p> <p>Bayer: Received honoraria and travel expenses from for participating in Advisory boards. Received honoraria for participating in educational activities related to stroke prevention in atrial fibrillation. Received travel and accommodation to attend an international cardiology meeting.</p> <p>Clinical lead for the West of England Academic Health Science Network “Don’t wait to anticoagulate” project promoting stroke prevention in atrial</p>	Personal, financial, non-specific and specific (Servier, Novartis)	<p>Declare and participate</p> <p>May be required to declare and withdraw if Ivabradine (Servier) and sacubitril/valsartan (Novartis) considered</p>

4.0.x DOC Cmte membership list

Committee membership list – Chronic heart failure guideline Committee

		fibrillation partly funded by Bayer.		
Richard Mindham	Lay member	Sits on the: National Heart Failure Audit. Royal Brompton & Harefield Trust's Patient Advisory Group for Heart Failure Research. Ironman Trial Steering Committee.	Personal, non-financial, non-specific	Declare and participate
Nick Hartshorne-Evans	Lay member	Remunerated by the Pumping Marvellous Foundation as the CEO. In the past 12 months The Pumping Marvellous Foundation have been grant funded by the following companies: Novartis, St Jude Medical, Servier	Personal, financial, non-specific Servier and Novartis non-personal, financial, specific	Declare and participate May be required to declare and withdraw if Ivabradine (Servier) and sacubitril/valsartan (Novartis) considered

Date last reviewed: 30/03/2016